The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice.
Zbigniew DoniecMagdalena Olszanecka-GilianowiczPiotr HantulikAgnieszka Almgren-RachtanJerzy ChudekPublished in: The Journal of asthma : official journal of the Association for the Care of Asthma (2022)
Salflumix Easyhaler is highly effective and well-tolerated by naïve patients with asthma and those switching from another device. In general, patients show good compliance with medical product and are satisfied with the use of this new device, and not reporting difficulties and errors related to its' use. Their physicians' overall perception of Salflumix Easyhaler use is very positive.
Keyphrases
- patient satisfaction
- end stage renal disease
- clinical practice
- chronic obstructive pulmonary disease
- ejection fraction
- lung function
- newly diagnosed
- chronic kidney disease
- healthcare
- randomized controlled trial
- systematic review
- primary care
- prognostic factors
- adverse drug
- peritoneal dialysis
- emergency department
- allergic rhinitis
- patient reported outcomes
- combination therapy
- patient reported
- replacement therapy
- smoking cessation
- drug induced
- clinical evaluation